Celgene has entered a definitive merger agreement to acquire US-based biopharmaceutical firm Juno Therapeutics for $87 per share, totalling approximately $9bn.

Juno primarily develops chimeric antigen receptor (CAR) T and T-cell receptor (TCR) therapeutics.

The firm’s JCAR017 (lisocabtagene maraleucel; liso-cel) candidate for the treatment of relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) is expected to bolster Celgene’s lymphoma portfolio.

Anticipated to obtain US regulatory approval next year, JCAR017 is estimated to potentially generate around $3bn in peak sales.

Celgene CEO Mark Alles said: “The acquisition of Juno builds on our shared vision to discover and develop transformative medicines for patients with incurable blood cancers.

“Juno’s advanced cellular immunotherapy portfolio and research capabilities strengthen Celgene’s global leadership in haematology and adds new drivers for growth beyond 2020.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The people at Juno channel their passion for science and patients towards a common goal of finding cures by creating cell therapies that help people live longer, better lives.”

The deal will further add complementary scientific platform and scalable manufacturing capabilities to support Celgene’s position in haematology and oncology segments.

Furthermore, Celgene intends to leverage Juno’s research and development facility in Seattle and the firm’s manufacturing facility in Bothell, Washington for expanding its existing centre of excellence for immuno-oncology translational medicine.

Juno Therapeutics president and CEO Hans Bishop said: “The people at Juno channel their passion for science and patients towards a common goal of finding cures by creating cell therapies that help people live longer, better lives.

“Continuing this work will take scientific prowess, manufacturing excellence and global reach. This union will provide all three.”

Subject to customary closing conditions, the acquisition is expected to be completed in the first quarter of this year.